ProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time
May 04 2023 - 8:30AM
ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech,
genomics and diagnostics company, will hold a conference call on
Thursday, May 11, 2023, at 11:00 a.m. Eastern time to discuss its
results for the first quarter ended March 31, 2023. A press release
detailing these results will be issued prior to the call.
ProPhase Labs’ CEO and Chairman of the Board of
Directors, Ted Karkus, will host the conference call, followed by a
question-and-answer period.
To access the call, please use the following
information:
Date: |
Thursday, May 11, 2023 |
Time: |
11:00 a.m. Eastern time, 8:00 a.m. Pacific time |
Participants can register for the conference
call by navigating to:
https://dpregister.com/sreg/10178710/f95cce1458
Please note that registered participants will
receive their dial in number upon registration. Pre-registration
required fields of information include: name, phone, company,
email.
Those without internet access or unable to
pre-register may dial in to the conference call by calling:
Toll free dial in number: |
1-866-777-2509 |
International dial in number: |
1-412-317-5413 |
Please call the conference telephone number 5-10
minutes prior to the start time. Please ask to be joined into the
ProPhase Labs, Inc. conference call. An operator will register your
name, phone and organization.
The conference call will be broadcast live and
available for replay at
https://event.choruscall.com/mediaframe/webcast.html?webcastid=bQyqnuoI
and via the investor relations section of the
Company's website at www.ProPhaseLabs.com.
A replay of the conference call will be
available two hours from when the call ends.
Toll-free replay number: |
1-877-344-7529 |
International replay number: |
1-412-317-0088 |
Replay Access Code: |
9261373 |
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”)
is a next-generation biotech, genomics and diagnostics company. Our
goal is to create a healthier world with bold action and the power
of insight. We’re revolutionizing healthcare with industry-leading
Whole Genome Sequencing solutions, while developing potential game
changer diagnostics and therapeutics in the fight against cancer.
This includes a potentially life-saving cancer test focused on
early detection of esophageal cancer and potential breakthrough
cancer therapeutics with novel mechanisms of action. Our
world-class CLIA labs and cutting-edge diagnostic technology
provide wellness solutions for healthcare providers and consumers.
We develop, manufacture, and commercialize health and wellness
solutions to enable people to live their best lives. We are
committed to executional excellence, smart diversification, and a
synergistic, omni-channel approach. ProPhase Labs’ valuable
subsidiaries, their synergies, and significant growth underscores
our multi-billion dollar potential.
For more information, visit
www.ProPhaseLabs.com.
ProPhase Media Relations and
Institutional Investor Contact:ProPhase Labs,
Inc.267-880-1111investorrelations@prophaselabs.com
ProPhase Retail Investor Relations
Contact:Renmark Financial CommunicationsJohn
Boidman514-939-3989Jboidman@renmarkfinancial.com
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2024 to May 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From May 2023 to May 2024